TCM
STOK icon

Tekla Capital Management’s Stoke Therapeutics STOK Stock Holding History

Tekla Capital Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-99,263
Closed -$2.52M – 178
2021
Q3 		$2.52M Buy
+99,263
New +$2.77M 0.08% 131

Other funds holding STOK

ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Tekla Capital Management's STOK Position: Q4 2021 in Review

Tekla Capital Management sold out of Stoke Therapeutics (STOK) in Q4 2021, closing a stake of 99,263 shares — an estimated $2.52M sold.

Tekla Capital Management first reported a position in STOK in Q3 2021 and held it in 1 quarter. The position peaked at $2.52M in Q3 2021. 94 funds tracked by Wall St. Rank hold STOK as of Q4 2021.

  • Tekla Capital Management reported no remaining Stoke Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Tekla Capital Management sold 99,263 Stoke Therapeutics shares in Q4 2021, an estimated $2.52M.
  • Tekla Capital Management first reported a position in Stoke Therapeutics in Q3 2021 and held it in 1 quarter.
  • Tekla Capital Management's Stoke Therapeutics position peaked at $2.52M in Q3 2021.
  • 94 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q4 2021.

Based on Tekla Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.